Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer

A promising molecular target for aggressive cancers is the urokinase receptor (uPAR). A fully human, recombinant antibody that binds uPAR to form a stable complex that blocks uPA-uPAR interactions (2G10) and is internalized primarily through endocytosis showed efficacy in a mouse xenograft model of...

Descripción completa

Detalles Bibliográficos

Autores principales:	Efrat T. Harel, Penelope M. Drake, Robyn M. Barfield, Irene Lui, Shauna Farr-Jones, Laura Van’t Veer, Zev J. Gartner, Evan M. Green, André Luiz Lourenço, Yifan Cheng, Byron C. Hann, David Rabuka, Charles S. Craik
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	MDPI AG 2019-11-01
Colección:	Antibodies
Materias:	antibody-drug conjugate (adc) urokinase receptor (upar) targeted therapy triple-negative breast cancer (tnbc) cleavable linker non-cleavable linker site-specific conjugations monomethyl auristatin e (mmae) maytansinoid
Acceso en línea:	https://www.mdpi.com/2073-4468/8/4/54
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!